CN113956227A - 黄酮类化合物及其合成方法和用途 - Google Patents
黄酮类化合物及其合成方法和用途 Download PDFInfo
- Publication number
- CN113956227A CN113956227A CN202010701196.2A CN202010701196A CN113956227A CN 113956227 A CN113956227 A CN 113956227A CN 202010701196 A CN202010701196 A CN 202010701196A CN 113956227 A CN113956227 A CN 113956227A
- Authority
- CN
- China
- Prior art keywords
- och
- compound
- dmso
- nmr
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930003935 flavonoid Natural products 0.000 title claims abstract description 21
- 235000017173 flavonoids Nutrition 0.000 title claims abstract description 21
- -1 Flavonoid compound Chemical class 0.000 title claims abstract description 17
- 238000001308 synthesis method Methods 0.000 title abstract description 3
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract 5
- 229940124599 anti-inflammatory drug Drugs 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 33
- 238000003786 synthesis reaction Methods 0.000 abstract description 33
- 150000001875 compounds Chemical class 0.000 abstract description 31
- 238000006243 chemical reaction Methods 0.000 abstract description 27
- 239000002994 raw material Substances 0.000 abstract description 11
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 abstract description 10
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 8
- 229930003944 flavone Natural products 0.000 abstract description 8
- 235000011949 flavones Nutrition 0.000 abstract description 8
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 8
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 abstract description 7
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 abstract description 7
- 235000010209 hesperetin Nutrition 0.000 abstract description 7
- 229960001587 hesperetin Drugs 0.000 abstract description 7
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 abstract description 7
- 229930182470 glycoside Natural products 0.000 abstract description 5
- 150000002611 lead compounds Chemical class 0.000 abstract description 4
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 abstract description 3
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 abstract description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 abstract description 3
- 150000007946 flavonol Chemical class 0.000 abstract description 3
- 235000011957 flavonols Nutrition 0.000 abstract description 3
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 abstract description 3
- 238000006264 debenzylation reaction Methods 0.000 abstract description 2
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 123
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 33
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 32
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 32
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 24
- 238000001914 filtration Methods 0.000 description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 239000012046 mixed solvent Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 239000005457 ice water Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000012266 salt solution Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- HGDWHTASNMRJMP-UHFFFAOYSA-N [1-(hydroxyamino)-1-oxo-5-(3-phenoxyphenyl)pentan-2-yl]phosphonic acid Chemical compound ONC(=O)C(P(O)(O)=O)CCCC1=CC=CC(OC=2C=CC=CC=2)=C1 HGDWHTASNMRJMP-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- HDMGAZBPFLDBCX-UHFFFAOYSA-M potassium;sulfooxy sulfate Chemical compound [K+].OS(=O)(=O)OOS([O-])(=O)=O HDMGAZBPFLDBCX-UHFFFAOYSA-M 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- NYWRBDSLXCKNAJ-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoyl bromide Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(Br)=O NYWRBDSLXCKNAJ-SQOUGZDYSA-N 0.000 description 3
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 3
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 3
- 229940025878 hesperidin Drugs 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- NYWRBDSLXCKNAJ-MGCNEYSASA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanoyl bromide Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(Br)=O NYWRBDSLXCKNAJ-MGCNEYSASA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 2
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 2
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PVVWHFBGCYENAP-RKQHYHRCSA-N [(2r,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-bromo-6-hydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@](O)(Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O PVVWHFBGCYENAP-RKQHYHRCSA-N 0.000 description 2
- PVVWHFBGCYENAP-MBJXGIAVSA-N [(2r,3s,4s,5r,6r)-3,4,5-triacetyloxy-6-bromo-6-hydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@](O)(Br)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]1OC(C)=O PVVWHFBGCYENAP-MBJXGIAVSA-N 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000002388 hesperetin derivatives Chemical class 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 2
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DGJMHKMYSDYOFP-MRXNPFEDSA-N C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O Chemical compound C=CC(N(CCC1)C[C@@H]1N1N=C(C2=CN(CC(C3=CC=CC=C3)(F)F)N=N2)C2=C(N)N=CN=C12)=O DGJMHKMYSDYOFP-MRXNPFEDSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- BEXZJJQVPWJPOA-VOTSOKGWSA-N [(e)-hept-2-enyl] 6-methyl-4-(4-nitrophenyl)-2-oxo-3,4-dihydro-1h-pyrimidine-5-carboxylate Chemical compound CCCC\C=C\COC(=O)C1=C(C)NC(=O)NC1C1=CC=C([N+]([O-])=O)C=C1 BEXZJJQVPWJPOA-VOTSOKGWSA-N 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
半合成黄酮类化合物及其抗炎用途。本发明属于医药技术领域,具体是天然产物之衍生物的合成及其在抗炎方面的应用,更具体的是黄酮类化合物的合成方法和在抗炎的用途。本发明以橙皮素为原料,合成了黄酮醇苷元,最后通过脱苄基与乙酰基反应合成黄酮苷。共合成了32个黄酮化合物,包括14个黄酮苷元和18个黄酮苷,其中有15个已知化合物和17个未见报道的化合物。部分化合物表现出较好的体外抗炎活性,有可能成为抗炎药物或先导化合物。
Description
技术领域
本发明属于医药技术领域,具体是天然产物之衍生物的合成及其在抗癌方面的应用。
背景技术
黄酮类化合物是一类具有15个碳原子组成的天然有机化合物(C6-C3-C6),骨架中含两个苯环,两个苯环由一个C3部分桥连,C3部分可以是脂肪链,也可以与C6部分形成五元或六元氧杂环。黄酮类化合物广泛存在食物和药物中,是许多天然药用植物中的主要活性成分之一,具有广泛的生物活性,如抗炎、抗氧化、抗肿瘤、保护心血管、抗菌、降血糖等药理作用。黄酮类化合物不仅结构多样,而且不同类型的化合物表现出不同的生物活性和功能。
据报道,全国每年产生柑橘类皮渣1000多万吨,约含类黄酮1万吨,其中二氢黄酮类化合物橙皮苷、橙皮素含量较高,分别约为2.9%和1.0%,其具有抗炎、抗氧化、抗肿瘤、保护心血管、免疫调节等多种生物活性。然而,橙皮苷、橙皮素因水溶性较差,生物利用度低等缺点,使其不能发挥其药理作用,限制了开发其潜在的药用价值。在对天然黄酮类化合物的研究开发利用过程中,将分布广泛、含量较高、活性低的天然黄酮类化合物半合成为含量较低、生理活性更强的黄酮类化合物、药物或先导化合物,是一种对天然黄酮类化合物资源的合理利用,同时,具有合成步骤少、生产成本低的优点,对黄酮类化合物工业上的开发具有重要意义。
乳腺癌是女性最常见的恶性肿瘤之一,其发病率在女性恶行肿瘤中居于前列。根据受体类型不同,乳腺癌可分为四种亚型:Luminal A、Luminal B、HER2过表达以及三阴型。其中,三阴型乳腺癌(TNBC)是缺乏雌激素受体(ER),孕激素受体(PR)和人表皮生长因子受体2(HER2)的表达,占所有乳腺癌类型的15%~20%。但是因其恶性程度高、侵袭力强、易复发、易转移、预后差,其被认为是乳腺癌中最凶险的类型。因此发掘具有抗三阴性乳腺癌活性的药物,并寻找相应的作用靶点具有重要的研究意义。黄酮类化合物具有广泛的生物活性,其中抗肿瘤活性有较多报道,有可能成为抗三阴型乳腺癌药物或先导化合物。
本发明以橙皮素为原料半合成其衍生物,并进行体外抗人三阴性乳腺癌活性实验。
发明内容
本发明的目的是探索以橙皮素为原料半合成其衍生物,探寻有可能成为抗三阴型乳腺癌药物或先导化合物。
本发明解决上述技术问题的技术方案如下:
以橙皮素为原料,经选择性甲基化、氧化、苄基化等反应步骤共合成了苄基保护黄酮醇苷元(合成路线图如附图1所示),然后在DMF/K2CO3条件下,与全乙酰化溴代糖进行糖苷缩合反应,最后通过脱苄基与乙酰基反应合成黄酮苷(合成路线图如附图2所示)。共合成了32个黄酮化合物,包括14个黄酮苷元和18个黄酮苷,其中有15个已知化合物和17个新化合物(结构如表1所示)。
溴代-2,3,4,6-四-O-乙酰基-α-D-葡萄糖1p、溴代-2,3,4,6-四-O-乙酰基-α-D-半乳糖1s的制备方法:先将葡萄糖或半乳糖的羟基全部乙酰化,再在红磷和溴的条件下,将乙酰基糖的异头碳溴化的一锅法合成(合成路线如附图3与附图4所示)。
表1中间体与目标化合物(标有*为未见报道的化合物)
附图说明
图1为黄酮苷元的合成路线图
图2为黄酮苷的合成路线图
图3为溴代-2,3,4,6-四-O-乙酰基-α-D-葡萄糖的合成路线图
图4为溴代-2,3,4,6-四-O-乙酰基-α-D-半乳糖的合成路线图
具体实施方式
下面结合实施例对本发明作进一步描述。
实施例1
化合物1a的合成
橙皮素(3.5g,11.6mmol)溶于350mL干燥无水丙酮中,再加入无水碳酸钾(1.6g,11.6mol),加热回流搅拌1.5h后缓慢滴加碘甲烷(1.0mL,15.4mmol),加热回流17h,滤除无水碳酸钾,蒸去丙酮,得黄色粉末粗品3.8g,经硅胶柱层析(环己烷/乙酸乙酯=2∶1,体积比,其余同),得黄色针晶固体1a(2.75g,产率75.5%)和化合物2a(206mg,产率5.6%)。
化合物1a:m.p.161~162℃;1H-NMR(DMSO-d6,600MHz)δ:12.10(s,1H,5-OH),9.10(s,1H,3′-OH),6.93(d,J=6.0,1H,H-5′),6.92(s,1H,H-2′),6.86(dd,J=8.4,1.8Hz,1H,H-6′),6.10(d,J=1.8Hz,1H,H-6),6.07(d,J=2.4Hz,1H,H-8),5.48(dd,J=12.6,3.0Hz,1H,H-2),3.78(s,3H,7-OCH3),3.76(s,3H,4′-OCH3),3.24(dd,J=16.2,12.0Hz,1H,H-3b),2.72(dd,J=17.4,3.0Hz,1H,H-3a)。13C-NMR(DMSO-d6,150MHz)δ:196.8(C-4),167.4(C-7),163.2(C-5),162.7(C-9),147.9(C-4),146.5(C-3),131.0(C-1′),117.7(C-6′),114.1(C-5′),111.9(C-2′),102.6(C-10),94.6(C-6),93.8(C-8),78.4(C-2),55.9(7-OCH3),55.7(4′-OCH3),42.1(C-3);ESI-MS m/z:315[M-H]-,317[M+H]+。
化合物2a:m.p.163~164℃;1H-NMR(DMSO-d6,600MHz)δ:12.09(s,1H,5-OH),7.11(d,J=1.8Hz,1H,H-5′),7.01(dd,J=7.8,1.8Hz,1H,H-2′),6.95(d,J=7.8Hz,1H,H-6′),6.10(d,J=1.8Hz,1H,H-6),6.06(d,J=2.4Hz,1H,H-8),5.51(dd,J=12.6,3.0Hz,1H,H-2),3.76(s,3H,7-OCH3),3.74(s,3H,4-OCH3),3.73(s,3H,4′-OCH3),3.36(t,J=17.4Hz,1H,H-3b),2.74(dd,J=17.4,3.0Hz,1H,H-3a)。13C-NMR(DMSO-d6,150MHz)δ:196.9(C-4),167.5(7-C),163.2(C-5),162.8(C-9),149.1(C-4),148.7(C-3),130.8(C-1′),119.3(C-6′),111.5(C-5′),110.6(C-2′),102.6(C-10),94.7(C-6),93.9(C-8),78.7(2-C),56.0(4′-OCH3),55.6(2C,7,3′-OCH3),42.2(3-C);ESI-MS m/z:329[M-H]-,331[M+H]+。
实施例2
化合物1b的合成
化合物1a(2.5g,7.9mmol)溶于40mL干燥吡啶中,再加入碘单质(2.4g,7.5mmol),90℃条件下反应,TLC跟踪反应进程,原料点消失停止反应,冷却至室温后,在剧烈搅拌下缓慢加入冰水,析出棕黑色固体,抽滤,滤饼用3%稀盐酸洗至无吡啶味,再用饱和硫代硫酸钠除去未反应的碘单质,烘干得黄色粗品,无水乙醇重结晶得黄色针晶2.0g,产率93.9%。m.p.162~163℃;1H-NMR(DMSO-d6,600MHz)δ:12.92(s,1H,5-OH),9.44(s,1H,3′-OH),7.56(dd,J=8.4,2.4Hz,1H,H-6′),7.45(d,J=2.4Hz,1H,H-2′),7.09(d,J=8.4Hz,1H,H-5′),6.81(s,1H,3-H),6.75(d,J=1.8Hz,1H,H-8),6.37(d,1H,J=2.4Hz,H-6),3.86(s,6H,7,4′-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:181.9(C-4),165.2(C-2),163.9(C-7),161.2(C-5),157.3(C-9),151.3(C-4′),146.8(C-3′),122.9(C-1′),118.8(C-6′),113.1(C-2′),112.1(C-5′),104.7(C-10),103.7(C-3),98.0(C-6),92.7(C-8),56.1(4′-OCH3),55.8(7-OCH3);ESI-MS m/z:313[M-H]-,315[M+H]+。
实施例3
化合物1c的合成
橙皮素(5.0g,15.8mmol)溶于80mL干燥吡啶中,再加碘单质(4.8g,15mmol),90℃条件下反应,TLC跟踪反应进程,原料点消失停止反应,冷却到室温后,在剧烈搅拌下缓慢加入冰水,析出棕黑色固体,抽滤,滤饼用3%稀盐酸洗至无吡啶味,再用饱和硫代硫酸钠除去未反应的碘单质,烘干得黄色粗品,无水乙醇重结晶得黄色粉末4.5g,产率90.5%。m.p.254~255℃;1H-NMR(DMSO-d6,600MHz)δ:12.73(s,1H,5-OH)7.46(s,1H,H-2′),7.23(d,J=8.4Hz,1H,6′-H),6.92(d,J=8.4Hz,1H,H-5′),6.30(s,1H,H-3),5.92(s,1H,H-8),5.55(s,1H,H-6),3.79(3H,s,4′-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:179.1(C-4),177.4(C-2),161.1(C-7),161.0(C-5),158.3(C-9),150.7(C-4′),149.2(C-3′),124.0(C-1′),115.7(C-6′),112.7(C-2′),112.0(C-5′),102.7(C-10),102.1(C-3),98.7(C-6),96.7(C-8),55.5(4′-OCH3);ESI-MS m/z:299[M-H]-,301[M+H]+。
实施例4
化合物1d的合成
第一种合成路径:
化合物1c(2.0g,6.67mmol)溶于350mL干燥无水丙酮中,再加入无水碳酸钾(2.0g,14.5mol),加热回流搅拌1.5h后缓慢滴加碘甲烷(1.3mL,20.0mmol),加热回流17h,滤除无水碳酸钾,蒸去丙酮,得黄色粉末粗品2.5g,过硅胶柱层析(环己烷/乙酸乙酯=2∶1),得黄色粉末1.9g,产率87%。
第二种合成路径:
化合物2a(200mg,0.6mmol)溶于5mL干燥吡啶中,再加入碘单质(200mg,0.62mmol),90℃条件下反应,TLC跟踪反应进程,原料点消失停止反应,冷却到室温后在剧烈搅拌下缓慢加入冰水,析出棕黑色固体,抽滤,滤饼用3%稀盐酸洗至无吡啶味,再用饱和硫代硫酸钠除去未反应的碘单质,烘干得粗品,无水乙醇重结晶得黄色粉末160mg,产率84%。m.p.164~165℃;1H-NMR(DMSO-d6,600MHz)δ:12.90(s,1H,5-OH),7.72(dd,J=8.4,1.8Hz,1H,H-6′),7.58(d,J=1.8Hz,1H,H-2′),7.14(d,J=9.0Hz,1H,H-5′),7.03(s,1H,H-3),6.81(d,J=2.4Hz,1H,H-8),6.38(d,J=1.8Hz,1H,H-6),3.89(3H,s,4′-OCH3),3.88(s,3H,3′-OCH3),3.86(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:182.0(C-4),165.2(C-2),163.6(C-7),161.1(C-5),157.3(C-9),152.2(C-4′),149.0(C-3′),122.7(C-1′),120.1(C-6′),111.6(C-5′),109.4(C-2′),104.7(C-10),104.0(C-3),98.0(C-6),92.7(C-8),56.1(7-OCH3),55.9(4′-OCH3),55.7(3′-OCH3);ESI-MS m/z:327[M-H]-,329[M+H]+。
实施例5
化合物1e的合成
化合物1b(2.0g,9.3mmol)溶于100mL干燥无水丙酮中,再加入无水碳酸钾(13.0g,94.2mmol),加热回流搅拌1.5h后缓慢滴加溴化苄(2.6mL,20.0mmol),继续回流反应,TLC跟踪反应进程,原料点消失停止反应,冷却至室温,滤除碳酸钾,减压回收溶剂,得黄色粗品,经硅胶柱层析(环己烷/乙酸乙酯=2∶1)得黄色粉末2.1g,产率67.8%。1H-NMR(DMSO-d6,600MHz)δ:7.29-7.66(m,12H,5,3′-Bn-Ar,H-2′,H-6′),7.12(d,J=14.4Hz,1H,5′-H),6.85(d,J=2.4Hz,1H,H-8),6.73(s,1H,H-3),6.59(d,J=1.8Hz,1H,H-6),5.22(d,J=4.2Hz,4H,5,3′-Bn-CH2),3.88(s,3H,4′-OCH3),3.84(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:175.7(C-4),163.5(C-2),159.7(C-7),159.1(C-5),158.9(C-9),151.9(C-4′),148.0(C-3′),126.9-136.9(12C,5,3′-O-Bn-Ar),123.0(C-1′),119.7(C-6′),111.9(C-2′),110.8(C-5′),108.7(C-10),107.1(C-3),97.7(C-6),93.7(C-8),70.2(3′-O-Bn-CH2),69.8(7-O-Bn-CH2),56.0(4′-OCH3),55.8(7-OCH3);ESI-MS m/z:493[M-H]-,495[M+H]+。
实施例6
化合物1f的合成
化合物1d(2.0g,5.89mmol)溶于100mL无水丙酮中,再加入无水碳酸钾(8.0g,58.0mmol),回流搅拌1h后,缓慢滴加溴化苄(1.0mL,7.7mmol),继续加热回流,TLC跟踪反应进程,原料点消失停止反应,冷却至室温,滤除碳酸钾,减压回收溶剂,得黄色粗品,经硅胶柱层析(环己烷/乙酸乙酯=2∶1)得浅黄色粉末1.8g,产率71.8%。1H-NMR(DMSO-d6,600MHz)δ:7.66(dd,J=1.8Hz,1H,H-6′),7.62(d,J=1.8Hz,2H,H-2′,Bn-Ar),7.31-7.43(m,4H,Bn-Ar),7.12(d,J=8.4Hz,1H,H-5′),6.89(d,J=1.8Hz,1H,H-8),6.76(s,1H,H-3),6.61(d,J=2.4Hz,1H,6-H),5.24(s,2H,5-Bn-CH2),3.90(s,3H,4′-OCH3),3.89(3H,s,3′-OCH3),3.85(3H,s,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:175.7(C-4),163.5(C-2),159.7(C-7),159.1(C-5),158.9(C-9),151.6(C-4′),149.0(C-3′),126.8-136.9(6C,Bn-Ar-C),123.1(C-1′),119.4(C-6′),111.6(C-2′),109.1(C-5′),108.7(C-10),107.1(C-3),97.7(C-6),93.7(C-8),69.8(Bn-CH2),56.0(4′-OCH3),55.9(3′-OCH3),55.7(7-OCH3);ESI-MS m/z:417[M-H]-,419[M+H]+。
实施例7
化合物1g的合成
化合物1c(2.4g,7.9mmol)溶于100mL干燥的丙酮中,再加入无水碳酸钾(11g,80mmol),加热回流搅拌1h后,缓慢滴加溴化苄(3.3mL,25mmol),继续搅拌回流反应,TLC跟踪反应进程,原料点消失停止反应,冷却至室温,滤除碳酸钾,蒸去丙酮,得黄色粗品,经硅胶柱层析(环己烷/乙酸乙酯=2∶1)得黄色固体3.0g,产率65%。m.p.153~154℃;1H-NMR(DMSO-d6,600MHz)δ:7.31-7.66(m,17H,5,7,3′-Bn-Ar,H-2′,H-6′),7.16(d,J=9.6Hz,1H,H-5′),7.00(d,J=1.8Hz,1H,H-8),6.75(s,1H,H-3),6.71(d,J=1.8Hz,1H,H-6),5.26(s,2H,3′-O-Bn-CH2),5.25(s,2H,7-O-Bn-CH2),5.24(s,2H,5-O-Bn-CH2),3.87(s,3H,4′-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:175.6(C-4),162.5(C-2),159.6(C-7),159.0(2C,C-5,C-9),151.9(C-4′),148.0(C-3′),123.6-136.8(18C,Bn-Ar-C),123.0(C-1′),119.7(C-6′),112.0(C-2′),110.8(C-5′),108.8(C-10),107.1(C-3),94.6(C-6),91.1(C-8),70.2(3′-O-Bn-CH2),70.0(7-O-Bn-CH2),69.8(5-O-Bn-CH2),55.8(4′-OCH3);ESI-MS m/z:569[M-H]-,571[M+H]+。
实施例8
化合物1h的合成
化合物1e(1.6g,3.2mmol)溶于140mL二氯甲烷/丙酮(v/v=4∶3)混合溶剂中,加200mL Na2CO3/NaHCO3缓冲溶液(Na2CO38.0g,NaHCO33.8g),在室温下剧烈搅拌,并用恒压漏斗缓慢滴加过硫酸氢钾复合盐溶液(12g,140mL),6h滴完,反应21h后,再缓慢滴加140mL过硫酸氢钾复合盐溶液(12g,140mL),约6h滴完,TLC监控至原料点消失,停止反应,静置分离有机相,水相用二氯甲烷(100mL×2)萃取,合并有机相,分别用饱和硫代硫酸钠(100mL×2)和饱和食盐水(100mL×2)洗涤有机相,无水硫酸钠干燥有机相,过滤,滤液中加入6mg对甲苯磺酸,继续在室温下反应2h,蒸干溶剂,得棕色粗品,二氯甲烷/甲醇重结晶得黄色粉末1.0g,产率62.0%。1H-NMR(DMSO-d6,600MHz)δ:9.16(s,1H,3-OH),7.31-7.87(m,12H,5,3′-O-Bn-Ar,H-2′,H-6′),7.15(d,J=9.0Hz,1H,H-5′),6.84(d,J=1.8Hz,1H,H-8),6.61(d,J=2.4Hz,1H,H-6),5.26(s,2H,3′-O-Bn-CH2),5.18(s,2H,5-O-Bn-CH2),3.93(s,3H,4′-OCH3),3.86(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:171.2(C-4),163.6(C-2),158.8(C-7),158.0(C-5),150.3(C-9),147.5(C-4′),141.6(C-3′),138.2(C-3),126.6-136.9(12C,5,3′-O-Bn-Ar),123.5(C-1′),121.2(C-6′),112.3(C-2′),111.8(C-5′),106.6(C-10),96.8(C-6),93.1(C-8),70.3(3′-O-Bn-CH2),69.8(5-O-Bn-CH2),56.0(4′-OCH3),55.6(7-OCH3);ESI-MS m/z:509[M-H]-,511[M+H]+。
实施例9
化合物1i的合成
化合物1f(1.5g,3.5mmol)溶于140mL二氯甲烷/丙酮(v/v=4∶3)混合溶剂中,加200mL Na2CO3/NaHCO3缓冲溶液(8.0g Na2CO3,3.8g NaHCO3,200mL H2O),在室温下剧烈搅拌,并用恒压漏斗缓慢滴加140mL过硫酸氢钾复合盐溶液(12g,140mL H2O),约6h滴完,反应过夜后,再缓慢滴加140mL过硫酸氢钾复合盐溶液(12g,140mL H2O),约2h滴完,原料点消失,停止反应,静置分离有机相,水相用二氯甲烷(100mL×2)萃取,合并有机相,分别用饱和硫代硫酸钠(100mL×2)和饱和食盐水(100mL×2)洗涤有机相,无水硫酸钠干燥有机相,过滤,滤液中加入5mg对甲苯磺酸,在室温下反应2h,蒸干溶剂,得棕色固体,二氯甲烷/甲醇重结晶得黄色粉末0.97g,产率60.4%。1H-NMR(DMSO-d6,600MHz)δ:9.14(1H,s,3-OH),7.84(dd,J=8.4,1.8Hz,1H,H-6′),7.78(d,J=1.8Hz,1H,H-2′),7.70(d,J=2.8Hz,2H,5-O-Bn-Ar),7.42(t,J=15.6Hz,2H,5-O-Bn-Ar),7.33(t,J=15.0Hz,1H,5-O-Bn-Ar),7.147.70(d,J=9.0Hz,1H,H-5′),6.88(d,J=1.8Hz,1H,H-8),6.61(d,J=1.8Hz,1H,H-6),5.26(s,2H,5-O-Bn-CH2),3.91(s,3H,4′-OCH3),3.85(s,3H,3′-OCH3),3.84(3H,s,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:171.2(C-4),163.6(C-2),158.8(C-7),158.0(C-5),149.9(C-9),148.4(C-4′),141.8(C-3′),138.1(C-3),126.6-136.9(6C,5-O-Bn-Ar),123.6(C-1′),120.8(C-6′),111.5(C-2′),110.5(C-5′),106.6(C-10),96.8(C-6),93.1(C-8),69.8(5-O-Bn-CH2),56.0(7-OCH3),55.7(4′-OCH3),55.6(3′-OCH3),;ESI-MS m/z:433[M-H]-,435[M+H]+。
实施例10
化合物1j的合成
化合物1g(2.0g,3.5mmol)溶于140mL二氯甲烷/丙酮(v/v=4∶3)混合溶剂中,加200mL Na2CO3/NaHCO3缓冲溶液(8.0g Na2CO3,3.8g NaHCO3,200mL H2O),在室温下剧烈搅拌,并用恒压漏斗缓慢滴加140mL过硫酸氢钾复合盐溶液(12g,140mL H2O),约6h滴完,反应12h后,再缓慢滴加140mL过硫酸氢钾复合盐溶液(12g,140mL H2O),约6h滴完,原料点消失,停止反应,静置分离有机相,水相用二氯甲烷(100mL×2)萃取,合并有机相,分别用饱和硫代硫酸钠(100mL)和饱和食盐水(100mL)洗涤有机相,无水硫酸钠干燥有机相,过滤,滤液中加入5mg对甲苯磺酸,在室温下反应2h,蒸干溶剂,得棕色油状物,无水乙醇重结晶的黄色粉末1.2g,产率58.5%。m.p.159~160℃;1H-NMR(DMSO-d6,600MHz)δ:9.16(s,1H,3-OH),7.85(s,1H,H-2′),7.30-7.68(m,16H,7,5,3′-O-Bn-Ar,H-6′),7.16(d,J=8.4Hz,1H,H-5′),6.96(s,1H,H-8),6.70(d,J=1.8Hz,1H,H-6),5.25(s,4H,7,3′-O-Bn-CH2),5.16(s,2H,5-O-Bn-CH2),3.84(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:171.2(C-4),162.7(C-2),158.9(C-7),157.9(C-5),150.3(C-9),147.5(C-4′),141.7(C-3′),138.2(C-3),126.6-136.9(18C,5,7,3′-O-Bn-Ar-C),123.5(C-1′),121.2(C-6′),112.2(C-2′),111.9(C-5′),106.7(C-10),97.3(C-6),94.0(C-8),70.3(3′-O-Bn-CH2),70.1(7-O-Bn-CH2),69.8(5-O-Bn-CH2),55.7(4′-OCH3),;ESI-MS m/z:585[M-H]-,587[M+H]+。
实施例11
化合物1k的合成
化合物1h(51mg,0.1mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(90mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色粉末25mg,产率78%。1H-NMR(DMSO-d6,600MHz)δ:12.44(s,1H,5-OH),9.55(br s,1H,3-OH),9.32(s,1H,3′-OH),7.71(d,J=2.4H,1H,H-2′),7.68(dd,J=8.4,1.8Hz,1H,H-6′),7.08(d,J=8.4Hz,1H,H-5′),6.71(d,J=1.8Hz,1H,H-8),6.34(d,J=2.4Hz,1H,H-6),3.85(s,3H,4′-OCH3),3.84(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:176.1(C-4),165.0(C-2),160.4(C-7),156.1(C-5),149.4(C-9),146.8(C-4′),146.2(C-3′),136.5(3-C),123.4(C-1′),119.8(C-6′),114.7(C-2′),111.8(C-5′),104.1(C-10),97.5(C-6),91.9(C-8),56.0(4′-OCH3),55.6(7-OCH3);ESI-MS m/z:329[M-H]-,331[M+H]+。
实施例12
化合物1l的合成
化合物1i(50mg,0.12mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(90mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色粉末34mg,产率85%。1H-NMR(DMSO-d6,600MHz)δ:12.40(s,1H,5-OH),9.64(s,1H,3-OH),7.84(d,J=8.4Hz,1H,H-6′)7.75(s,1H,H-2′),7.13(d,J=8.4Hz,1H,H-5′),6.78(s,1H,H-8),6.34(s,1H,H-6),3.84(s,6H,3′,4′-OCH3),3.82(s,3H,7-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:176.1(C-4),165.0(C-2),160.4(C-7),156.2(C-5),150.5(C-9),148.4(C-4′),146.6(C-3′),1366(C-3),123.2(C-1′),121.6(C-6′),111.5(C-2′),110.9(C-5′),104.1(C-10),97.6(C-6),92.2(C-8),56.1(4′-OCH3),55.7(3′-OCH3),55.6(7-OCH3);ESI-MS m/z:323[M-H]-,325[M+H]+。
实施例13
化合物1m的合成
化合物化1j(50mg,0.08mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(90mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色粉末23mg,产率84%。m.p.143~144℃;1H-NMR(DMSO-d6,600MHz)δ:12.46(s,1H,5-OH),7.75(d,J=7.2Hz,1H,H-5′),7.69(dd,J=8.4,1.8Hz,1H,H-6′),7.47(d,J=1.8Hz,1H,H-2′),6.94(d,J=1.8Hz,1H,H-8),6.19(d,J=1.8Hz,1H,H-6),3.84(s,3H,4′-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:176.0(C-4),165.0(C-2),160.4(C-7),156.2(C-5),159.3(C-9),146.3(C-4′),146.2(C-3′),136.1(C-3),123.4(C-1′),119.7(C-6′),114.6(C-2′),111.8(C-5′),103.1(C-10),98.2(C-6),93.4(C-8),55.6(4′-OCH3)ESI-MS m/z:315[M-H]-,317[M+H]+。
实施例14
化合物1的合成
化合物1h(120mg,0.23mmol)溶于干燥的DMF(5mL)中,加无水K2CO3(110mg,0.80mmol),全乙酰化溴代葡萄糖(186mg,0.46mmol),在室温氮气保护下反应24h后,加20mL冰水猝灭,然后用3%稀盐酸调至中性,再用乙酸乙酯萃取(30mL×3),有机层用饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/乙酸乙酯=2∶1)得黄色固体112.6mg,产率60.0%。1H-NMR(DMSO-d6,600MHz)δ:7.81(d,J=1.8Hz,1H,H-2′),7.73(dd,J=8.4,2.4Hz,H-6′),7.63(d,J=7.2Hz,H-2′),7.32-7.63(m,10H,Bn-Ar),7.13(d,J=9.0Hz,1H,H-5′),6.80(d,J=1.8Hz,1H,H-8),6.62(d,J=2.4Hz,1H,H-6),5.72(d,J=7.8Hz,1H,H-1″),5.43(t,J=13.2Hz,1H,H-6″),5.24(d,J=6.6Hz,2H,3′-O-Bn-CH2),5.20(d,2H,J=4.2Hz,5-O-Bn-CH2),5.05(m,1H,H-6″),4.93(m,1H,H-5″),3.98(m,2H,,H-2″,H-3″),3.89(s,3H,4′-OCH3),3.86(s,3H,7-OCH3),3.93-3.84(m,1H,H-5″),2.08(s,3H,COCH3),1.95(s,6H,CH3CO),1.73(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:171.3(C-4),169.6,169.5,169.4,169.3(4C,Ac-CO×4),163.8(C-7),159.1(C-2),158.2(C-5),153.4(C-9),151.1(C-4′),147.0(C-3′),136.9(C-3),127.0-136.7(10C,Bn-Ar),122.4(C-1′),122.2(C-6′),113.8(C-2′),111.3(C-5′),108.5(C-10),98.3(C-1″),97.5(C-6),93.3(C-8),71.7(3′-O-Bn-CH2),71.6(5-O-Bn-CH2),70.4(C-3″),70.2(C-2″),70.0(C-4″),67.9(C-5″),61.1(C-6″),56.1(4′-OCH3),55.7(7-OCH3),20.6,20.4,20.3,20.0(4C,Ac-CH3);ESI-MS m/z:839[M-H]-,841[M+H]+。
实施例15
化合物2的合成
化合物1i(100mg,0.23mmol)溶于干燥的DMF(5mL)中,加无水K2CO3(220mg,1.6mmol),全乙酰化溴代葡萄糖(186mg,0.46mmol),在室温氮气保护下反应24h后,加20mL冰水猝灭,然后用3%稀盐酸调至中性,再用乙酸乙酯萃取(30mL×3),有机层用饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/乙酸乙酯=2∶1)得116.0mg白色固体化合物,产率65.8%。1H-NMR(DMSO-d6,600MHz)δ:7.76(d,J=1.8Hz,1H,H-2′),7.69(dd,J=9.0,2.4Hz,1H,H-6′),7.63(d,J=7.2Hz,2H,Bn-Ar),7.42(t,J=15.0Hz,2H,Bn-Ar),7.33(t,J=15Hz,1H,Bn-Ar),7.10(d,J=8.4Hz,1H,H-5′),6.85(d,J=2.4Hz,1H,H-8),6.62(d,J=2.4Hz,1H,H-6),5.74(d,J=7.8Hz,1H,H-1″),5.43(t,J=19.8Hz,1H,H-6″),5.24(d,J=6.6Hz,2H,5-O-Bn-CH2),5.02(m,1H,H-6″),4.90(m,1H,H-5″),3.99(m,1H,H-2″,H-3″),3.89(s,3H,4′-OCH3),3.88(s,3H,3′-OCH3),3.84(s,3H,7-OCH3),3.82(m,1H,H-5″),2.07(s,3H,CH3CO),1.96(s,3H,CH3CO),1.95(s,3H,CH3CO),1.79(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:171.3(C-4),169.6,169.5,169.4,169.3(4C,Ac-CO),163.8(C-7),159.1(C-2),158.2(C-5),153.4(C-9),150.8(C-4′),147.9(C-3′),136.7(C-3),127.0-135.3(5C,5-O-Bn-Ar),122.3(C-1′),121.8(C-6′),112.2(C-2′),111.0(C-5′),108.5(C-10),98.4(C-1″),97.5(C-6),93.4(C-8),71.7(5-O-Bn-CH2),71.6(C-3″),70.4(C-2″),70.0(C-4″),67.8(C-5″),61.0(C-6″),56.1(4′-OCH3),55.6(3′-OCH3),55.5(7-OCH3),20.5,20.4,20.3,20.0(4C,Ac-CH3);ESI-MS m/z:763[M-H]-,765[M+H]+。
实施例16
化合物3的合成
化合物1j(180mg,0.32mmol)溶于干燥的DMF(10mL)中,加K2CO3(330mg,2.4mmol),全乙酰化溴代葡萄糖(260mg,0.64mmol),在室温氮气保护下反应24h后,加30mL H2O稀释猝灭,然后用3%稀盐酸调至中性,再用乙酸乙酯萃取(40mL×3),饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/V乙酸乙酯=2∶1)得淡黄色固体148.5mg,产率53.4%。1H-NMR(DMSO-d6,600MHz)δ:7.82(d,J=2.4Hz,1H,H-2′),7.72(dd,J=8.4,2.4Hz,1H,H-6′),7.62(d,J=7.2Hz,2H,Bn-Ar),7.52(d,J=7.2Hz,2H,Bn-Ar),7.49(d,J=7.2Hz,2H,Bn-Ar),7.32-7.44(m,9H,Bn-Ar),7.14(d,J=9.0Hz,1H,H-5′),6.94(d,J=2.4Hz,1H,H-8),6.73(d,J=1.8Hz,1H,H-6),5.74(d,J=7.8Hz,1H,H-1″),5.44(t,J=19.2Hz,1H,H-6″),5.25(m,4H,7,3′-O-Bn-CH2),5.20(d,J=7.8Hz,2H,5-O-Bn-CH2),5.04-5.07(m,1H,H-6″),4.91-4.95(m,1H,H-5″),3.94-3.98(m,2H,H-2″,H-3″),3.86(s,3H,4′-OCH3),3.81-3.84(m,1H,H-4″),2.08(s,3H,CH3CO),1.96(s,6H,CH3CO),1.73(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:171.3(C-4),169.6,169.5,169.4,169.3(4C,Ac-CO),162.8(C-7),159.1(C-2),158.1(C-5),153.4(C-9),151.2(C-4′),147.0(C-3′),136.85(C-3),126.9-136.7(15C,Bn-Ar),122.4(C-1′),122.2(C-6′),113.8(C-2′),111.3(C-5′),108.6(C-10),98.3(C-1″),97.9(C-6),94.2(C-8),71.7,71.6,70.4(3C,Bn-CH2),70.2(C-3″),70.1(C-2″),70.0(C-4″),67.9(C-6″),61.1(C-5″),55.7(4′-OCH3),20.6,20.4,20.3,20.0(4C,Ac-CH3);ESI-MS m/z:915[M-H]-,917[M+H]+。
实施例17
化合物4的合成
化合物1h(100mg,0.20mmol)溶于干燥的DMF(5mL)中,加无水K2CO3(193mg,1.4mmol),全乙酰化溴代半乳糖(160mg,0.40mmol),在室温氮气保护下反应24h后,加20mL冰水猝灭,再用乙酸乙酯萃取(30mL×3),有机层用饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/乙酸乙酯=2∶1)得淡黄色固体108.0mg,产率69.0%。1H-NMR(DMSO-d6,600MHz)δ:7.95(d,J=2.4Hz,1H,H-2′),7.72(dd,J=8.4,1.8Hz,1H,H-6′),7.63(d,J=7.8Hz,2H,Bn-Ar),7.53(d,J=7.2Hz,2H,Bn-Ar),7.32-7.43(m,6H,Bn-Ar),7.10(d,J=9.0Hz,1H,H-5′),6.81(d,J=1.8Hz,1H,H-8).6.61(d,J=2.4Hz,1H,H-6),5.69(d,J=7.8Hz,1H,H-1″),5.26-5.36(m,2H,H-3″,H-5″),5.23(d,J=1.8Hz,2H,3′-O-Bn-CH2),5.18-5.20(m,3H,5-O-Bn-CH2,H-2″),4.19-4.21(t,J=12.6Hz,1H,H-4″),3.92-4.03(m,1H,H-6″),3.89(s,3H,4′-OCH3),3.85(s,3H,7-OCH3),3.80-3.84(m,1H,H-6″),2.10(s,3H,CH3CO),1.92(s,3H,CH3CO),1.79(s,3H,CH3CO),1.75(s,3H,4′-OCH3)。13C-NMR(DMSO-d6,150MHz)δ:171.4(C-4),169.8,169.7,169.6,169.42(4C,Ac-CO),163.8(C-7),159.1(C-2),153.0(C-5),151.2(C-4′),147.0(C-3′),136.9(C-3),127.0-136.7(12C,Bn-Ar),122.3(C-1′),122.0(C-6′),114.0(C-2′),111.3(C-5′),108.5(C-10),98.9(C-1″),97.5(C-6),93.3(C-8),70.2(7-O-Bn-CH2),70.0(2C,5,4′Bn-CH2),70.0(2C,C-2″,C-3″),69.2(C-4″),67.2(C-5″),60.7(C-6″),56.1(4′-OCH3),55.7(7-OCH3),20.7,20.4,20.2,19.9(4C,Ac-CH3);ESI-MS m/z:839[M-H]-,841[M+H]+。
实施例18
化合物5的合成
化合物1i(100mg,0.23mmol)溶于干燥的DMF(5mL)中,加无水K2CO3(220mg,1.6mmol),全乙酰化溴代半乳糖(186mg,0.46mmol),在室温氮气保护下反应24h后,加20mL冰水猝灭,然后用3%稀盐酸调至中性,再用乙酸乙酯萃取(30mL×3),有机层用饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/乙酸乙酯=2∶1)得白色固体112.7mg,产率64.0%。1H-NMR(DMSO-d6,600MHz)δ:7.91(d,J=1.8Hz,1H,H-2′),7.65(dd,J=8.4,1.8Hz,1H,H-6′),7.60(d,J=7.2Hz,2H,Bn-Ar),7.42(t,J=8.4Hz,2H,Bn-Ar),7.33(t,J=15Hz,1H,Bn-Ar),7.07(d,J=8.4Hz,1H,H-5′),6.84(d,J=1.8Hz,1H,H-8),6.60(d,J=1.8Hz,1H,H-6),5.70(d,J=8.4Hz,1H,H-1″),5.33(m,1H,H-5″),5.15-5.22(m,5H,5-O-Bn-CH2,H-2″,H-3″,H-4″),4.19(m,2H,H-6″),3.91(s,3H,4′-OCH3),3.87(s,3H,3′-OCH3),3.83(s,3H,7-OCH3),2.08(s,6H,CH3CO),1.92(s,3H,CH3CO),1.75(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:171.3(C-4),169.9,169.6,169.6,169.5(4C,Ac-CO),163.8(C-7),159.1(C-2),158.2(C-5),153.2(C-9),150.8(C-4′),147.8(C-3′),136.8(C-3),127.0-135.3(5C,Bn-Ar),122.33(C-1′),121.3(C-6′),112.4(C-2′),111.0(C-5′),108.5(C-10),98.8(C-1″),97.5(C-6),93.3(C-8),70.3(5-O-Bn-CH2),70.0(C-2″),69.9(C-3″),69.1(C-4″),67.2(C-5″),60.7(C-6″),56.1(4′-OCH3),55.7(3′-OCH3),55.5(7-OCH3),20.7,20.4,20.3,20.2(4C,Ac-CH3);ESI-MS m/z:763[M-H]-,765[M+H]+。
实施例19
化合物6的合成
化合物1j(200mg,0.36mmol)溶于干燥的DMF(10mL)中,加K2CO3(350mg,2.54mmol),全乙酰化溴代半乳糖(290mg,0.71mmol),在室温氮气保护下反应24h后,加30mL H2O稀释猝灭,然后用3%稀盐酸调至中性,再用乙酸乙酯萃取(40mL×3),饱和食盐水洗涤(100mL×2),无水MgSO4干燥,过滤,浓缩得黄色油状物,过硅胶柱色谱(环己烷/乙酸乙酯=2∶1)得白色固体182mg,产率65.5%。1H-NMR(DMSO-d6,600MHz)δ:7.96(s,1H,H-2′),7.72(dd,J=8.4,1.8Hz,1H,H-6′),7.62(d,J=7.2Hz,2H,Bn-Ar),7.53(d,J=7.2Hz,2H,Bn-Ar),7.47(d,J=7.2Hz,2H,Bn-Ar),7.30-7.42(m,9H,Bn-Ar),7.12(d,J=9.0Hz,1H,H-5′),6.94(s,1H,H-8),6.70(s,1H,H-6),5.70(d,J=7.8Hz,1H,H-1″),5.26-5.35(m,2H,H-3″,H-5″),5.17-5.26(m,6H,5,3′-O-BnCH2,H-2″,H-4″),4.19(t,J=13.2Hz,1H,H-6″),3.85(s,3H,4′-OCH3),3.82-3.84(m,1H,H-6″),2.10(s,3H,CH3CO),1.92(s,3H,CH3CO),1.78(s,3H,CH3CO),1.74(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:171.36(C-4),169.81,169.70,169.57,169.43(4C,Ac-CO),162.83(C-7),159.13(C-2),158.08(C-5),153.03(C-4′),151.20(C-3′),146.99(C-10),136.87(C-3),126.94-136.75(15C,Bn-Ar-C),122.32(C-1′),121.99(C-6′),114.03(C-2′),111.33(C-5′),108.60(C10),98.89(C-1″),97.92(C-6),94.19(C-8),70.2(5-O-Bn-CH2),70.1(3′-O-Bn-CH2),70.0(5-O-Bn-CH2),70.0(C-2″),70.0(C-3″),69.2(C-4″),67.2(C-5″),60.7(C-6″),55.7(4′-OCH3),20.7,20.4,20.2,19.9(4C,Ac-CH3);ESI-MS m/z:915[M-H]-,917[M+H]+。
实施例20
化合物7的合成
化合物1(96mg,0.114mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(180mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色油状物74mg,产率98%。1H-NMR(DMSO-d6,600MHz)δ:12.49(s,1H,5-OH),9.41(s,1H,3′-OH),7.63(d,J=2.4Hz,1H,H-2′),7.60(dd,J=8.4,1.8Hz,1H,H-6′),7.06(d,J=8.4Hz,1H,H-5′),6.74(d,J=2.4Hz,1H,H-8),6.38(d,J=2.4Hz,1H,H-6),5.70(d,J=7.8Hz,1H,H-1″),5.36(t,J=19.2Hz,1H,H-6″),5.13(t,J=17.4Hz,1H,H-6″),5.01(t,J=19.2Hz,1H,H-5″),3.87-3.98(m,3H,H-2″,H-3″,H-4″),3.85(s,3H,4′-OCH3),3.84(s,3H,7-OCH3),2.02(s,3H,CH3CO),1.96(s,3H,CH3CO),1.95(s,3H,CH3CO),1.81(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.0(C-4),169.7,169.5,169.3,169.3(4C,Ac-CO),165.4(C-7),160.8(C-2),157.2(C-5),156.3(C-9),150.4(C-4′),146.0(C-3′),133.2(C-3),121.9(C-1′),121.1(C-6′),116.1(C-2′),111.3(C-5′),105.0(C-10),98.6(C-1″),98.1(C-6),92.4(C-8),71.9(C-3″),71.4(C-2″),70.6(C-5″),67.8(C-4″),61.0(C-6″),56.2(4′-OCH3),55.6(7-OCH3),20.5,20.4,20.3,20.1(4C,Ac-CH3);ESI-MS m/z:659[M-H]-,661[M+H]+。
实施例21
化合物8的合成
化合物2(90mg,0.118mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(180mg),在常温常压氢气氛围中共反应了12h,过滤除去Pd/C,浓缩回收溶剂得黄色油状物78.8mg,产率99%。1H-NMR(DMSO-d6,600MHz)δ:12.46(s,5-OH),7.74(d,J=2.4Hz,1H,H-2′),7.69(dd,J=8.4,1.8Hz,1H,H-6′),7.13(d,J=9.0Hz,1H,H-5′),6.80(d,J=1.8Hz,1H,H-8),6.40(d,J=1.8Hz,1H,H-6),5.72(d,J=8.4Hz,1H,H-1″),5.38(t,J=19.2Hz,1H,H-6″),5.02(t,J=18.0Hz,1H,H-6″),4.90(t,J=17.8Hz,1H,H-5″),3.97-4.00(m,2H,H-2″,H-3″),3.88(s,3H,4′-OCH3),3.87(s,3H,3′-OCH3),3.84(s,3H,7-OCH3),3.80-3.84(m,1H,H-4″),2.03,1.95,1.79(s,12H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:176.7(C-4),169.4,169.2,169.1,169.0(4C,Ac-CO),165.13(C-7),160.6(C-2),156.8(C-5),156.1(C-9),151.1(C-4′),147.6(C-3′),133.0(C-3),122.2(C-1′),121.6(C-6′),112.0(C-2′),110.8(C-5′),104.8(C-10),98.4(C-1″),97.8(C-6),92.4(C-8),71.4(C-3″),71.1(C-2″),70.4(C-5″),67.4(C-4″),60.7(C-6″),55.9(4′-OCH3),55.4(3′-OCH3),55.3(7-OCH3),20.2,20.1,20.0,19.8(4C,Ac-CH3);ESI-MS m/z:673[M-H]-,675[M+H]+。
实施例22
化合物9的合成
化合物3(225mg,0.273mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(180mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色油状物169mg,产率96%。1H-NMR(DMSO-d6,600MHz)δ:12.49(s,1H,5-OH),10.92(br-s,1H,7-OH),9.40(s,1H,3′-OH),7.57(d,J=1.8Hz,1H,H-2′),7.55(dd,J=9.0,2.4Hz,1H,H-6′),7.02(d,J=8.4Hz,1H,H-5′),6.41(d,J=1.8Hz1H,H-8),6.19(d,J=1.8Hz,1H,H-6),5.66(d,J=7.8Hz,1H,H-1″),5.34(t,J=19.2Hz,1H,H-6″),5.11(t,J=18.0Hz,1H,H-6″),4.99(t,J=18.6Hz,1H,H-5″),3.91-3.95(m,2H,H-2″,H-3″),3.84-3.86(m,1H,H-4″),3.82(s,3H,4′-OCH3),2.00,1.95,1.94,1.80(s,each 3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:176.8(C-4),169.8,169.5,169.3,169.3(4C,Ac-CO),164.4(C-7),161.2(C-2),156.8(C-5),156.4(C-9),150.3(C-4′),145.9(C-3′),133.0(C-3),122.0(C-1′),121.0(C-6′),115.9(C-2′),111.3(C-5′),104.0(C-10),98.8(C-1″),98.6(C-6),93.8(C-8),71.9(C-3″),71.4(C-2″),70.5(C-5″),67.8(C-4″),61.0(C-6″),55.6(4′-OCH3),20.5,20.4,20.3,20.1(4C,Ac-CH3);ESI-MS m/z:645[M-H]-,647[M+H]+。
实施例23
化合物10的合成
化合物4(100mg,0.119mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%pd/C(180mg),在常温常压氢气氛围中共反应了24h,过滤除去pd/C,浓缩回收溶剂得黄色油状物77mg,产率98%。1H-NMR(DMSO-d6,600MHz)δ:12.47(s,1H,5-OH),9.22(s,1H,3′-OH),7.62(dd,J=8.4,2.4Hz,1H,H-6′),7.52(d,J=1.8Hz,1H,H-2′),7.03(d,J=8.4Hz,H-5′),6.71(d,J=2.4Hz,1H,H-8),6.35(d,J=1.8Hz,1H,H-6),5.61(d,J=7.2Hz,1H,H-1″),5.22-5.24(m,1H,H-5″),5.16-5.20(m,3H,H-2″,H-3″,H-,4″),3.84(s,3H,4′-OCH3),3.83(s,3H,7-OCH3),3.79-3.82(m,2H,H-6″),2.10(s,3H,CH3CO),2.02(s,3H,CH3CO),1.90(s,3H,CH3CO),1.75(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.1(C-4),169.9,169.6,169.5,169.4(4C,Ac-CO),165.3(C-7),160.9(C-2),157.2(C-5),156.4(C-9),150.4(C-4′),146.0(C-3′),133.3(C-3),122.2(C-1′),121.5(C-6′),116.0(C-2′),111.2(C-5′),105.0(C-10),98.9(C-1″),98.1(C-6),92.4(C-8),70.2(2C,C-2″,C-3″),69.2(C-4″),67.1(C-5″),60.9(C-6″),56.2(4′-OCH3),55.7(7-OCH3),20.6,20.4,20.4,20.2(4C,Ac-CH3);ESI-MS m/z:659[M-H]-,661[M+H]+。
实施例24
化合物11的合成
化合物5(90mg,0.118mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(180mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色油状物78mg,产率98%。1H-NMR(DMSO-d6,600MHz)δ:12.51(s,5-OH),7.91(d,J=1.8Hz,1H,H-2′),7.68(dd,J=8.4,1.8Hz,1H,H-6′),7.12(d,J=9.0Hz,1H,H-5′),6.78(d,J=8.4Hz,1H,H-8),6.37(d,J=15Hz,1H,H-6),5.74(t,J=13.8Hz,1H,H-1″),5.31(m,1H,H-5″),5.22-5.25(m,2H,H-3″,H-2″),4.24(m,1H,H-4″),3.92(s,3H,4′-OCH3),3.86(s,6H,7,3′-OCH3),3.36-3.41(m,1H,H-6″),3.26-3.31(m,1H,H-6″),2.09,2.06,1.93,1.77(s,each3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.0(C-4),169.8,169.6,169.5,169.5(4C,Ac-CO),165.4(C-7),160.8(C-2),156.8(C-5),156.3(C-9),151.4(C-4′),147.9(C-3′),133.2(C-3),122.0(C-1′),121.9(C-6′),112.6(C-2′),111.1(C-5′),105.0(C-10),99.0(C-1″),98.1(C-6),92.6(C-8),70.3(C-2″),69.9(C-3″),68.9(C-4″),67.1(C-5″),60.7(C-6″),56.2(4′-OCH3),55.7(3′-OCH3),55.5(7-OCH3),20.6,20.3,20.3,20.2(4C,Ac-CH3);ESI-MSm/z:673[M-H]-,675[M+H]+。
实施例25
化合物12的合成
化合物6(90mg,0.118mmol)溶于10mL甲醇/四氢呋喃(v/v=1∶1)混合溶剂中,加入10%Pd/C(180mg),在常温常压氢气氛围中共反应了24h,过滤除去Pd/C,浓缩回收溶剂得黄色油状物78mg,产率98%。1H-NMR(DMSO-d6,600MHz)δ:12.51(s,1H,5-OH),9.24(s,1H,3′-OH),7.60(dd,J=9.0,2.4Hz,1H,H-6′),7.49(d,J=1.8Hz,1H,H-2′),7.01(d,J=9.0Hz,H-5′),6.40(d,J=1.8Hz,1H,H-8),6.19(d,J=1.8Hz,1H,H-6),5.62(d,J=7.8Hz,1H,H-1″),5.23-5.25(m,1H,H-5″),5.16-5.17(m,2H,H-2″,H-3″),4.15(t,J=18.6Hz,1H,H-4″),3.85(s,3H,4′-OCH3),3.80-3.82(m,2H,H-6″),2.12(s,3H,CH3CO),2.03(s,3H,CH3CO),1.91(s,3H,CH3CO),1.78(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.0(C-4),169.8,169.6,169.5,169.5(4C,Ac-CO),165.37(C-7),160.8(C-2),156.8(C-5),156.3(C-9),151.4(C-4′),147.9(C-3′),133.2(C-3),122.0(C-1′),121.9(C-6′),112.6(C-2′),111.1(C-5′),105.0(C-10),99.0(C-1″),98.1(C-6),92.6(C-8),70.3(C-2″),69.9(C-3″),68.9(C-4″),67.1(C-5″),60.7(C-6″),55.8(4′-OCH3),20.6,20.3,20.3,20.2(4C,Ac-CH3);ESI-MS m/z:645[M-H]-,647[M+H]+。
实施例26
化合物13的合成
化合物8(60mg,0.118mmol)溶于20mL无水甲醇中,加入5mg甲醇钠,在50℃条件下反应,TLC监测反应,原料点消失停止,冷却至室温,减压回收溶剂得黄色粗品,经硅胶柱色谱(二氯甲烷/甲醇=100∶0 to 5∶1)得黄色固体31mg,产率66.1%。1H-NMR(DMSO-d6,600MHz)δ:12.53(s,1H,5-OH),7.90(s,1H,H-2′),7.63(d,J=8.4Hz,1H,H-2′),7.09(d,J=8.4Hz,H-5′),6.73(s,1H,H-8),6.36(s,1H,H-6),5.56(d,J=7.2Hz,1H,H-1″),5.35(s,1H,4″-OH),5.05(s,1H,2″-OH),4.97(s,1H,3″-OH),4.39(s,1H,6″-OH),3.83(s,3H,4′-OCH3),3.82(s,3H,3′-OCH3),3.80(s,3H,7-OCH3),3.56(d,J=14.4Hz,1H,H-6″),3.08-3.22(m,5H,H-2″,H-3″,H-4″,H-5″,H-6″);13C-NMR(DMSO-d6,150MHz)δ:177.6(C-4),165.2(C-7),162.0(C-2),156.4(C-5),156.4(C-9),151.1(C-4′),148.0(C-3′),133.6(C-3),122.4(C-1′),122.0(C-6′),112.7(C-2′),111.2(C-5′),105.1(C-10),100.7(C-1″),98.0(C-6),92.4(C-8),77.5(C-2″),76.4(C-3″),74.3(C-4″),69.8(C-5″),60.6(C-6″),56.2(7-OCH3),55.7(3′-OCH3),55.6(4′-OCH3);ESI-MS m/z:505[M-H]-,507[M+H]+。
实施例27
化合物14的合成
化合物9(50mg,0.077mmol)溶于20mL无水甲醇中,加入5mg甲醇钠,在50℃条件下反应,TLC监测反应,原料点消失停止,冷却至室温,减压回收溶剂得黄色粗品,经硅胶柱色谱(二氯甲烷/V甲醇=100∶0 to 5∶1)得黄色固体32mg,产率86.5%。1H-NMR(DMSO-d6,600MHz)δ:12.56(s,1H,5-OH),7.67(dd,J=8.4,2.4Hz,1H,H-6′),7.53(d,J=2.4Hz,1H,H-2′),7.02(d,J=8.4Hz,H-5′),6.38(s,1H,H-8),6.17(s,1H,H-6),5.46(d,J=9.0Hz,1H,H-1″),5.27(s,1H,4″-OH),5.05(s,1H,2″-OH),4.94(s,1H,3″-OH),4.26(s,1H,6″-OH),3.82(s,3H,4′-OCH3),3.55(m,1H,H-6″),3.06-3.19(m,5H,H-2″,H-3″,H-4″,H-5″,H-6″);13C-NMR(DMSO-d6,150MHz)δ:177.49(C-4),164.46(C-7),161.3(C-2),156.4(C-5),155.8(C-9),150.3(C-4′),145.9(C-3′),133.60(C-3),122.7(C-1′),121.4(C-6′),115.7(C-2′),111.4(C-5′),104.0(C-10),100.8(C-1″),98.8(C-6),93.6(C-8),77.6(C-2″),76.5(C-3″),74.1(C-4″),80.0(C-5″),61.3(C-6″),55.7(4′-OCH3);ESI-MS m/z:477[M-H]-,479[M+H]+。
实施例28
化合物15的合成
化合物11(50mg,0.077mmol)溶于20mL无水甲醇中,加入5mg甲醇钠,在50℃条件下反应,TLC监测反应,原料点消失停止,冷却至室温,减压回收溶剂得黄色粗品,经硅胶柱色谱(二氯甲烷/甲醇=100∶0 to 5∶1)得黄色固体32mg,产率86.5%。1H-NMR(DMSO-d6,600MHz)δ:7.80(d,J=2.4Hz,1H,H-6′),7.64(d,J=9.0Hz,1H,H-2′),7.08(d,J=8.4Hz,H-5′),6.71(s,1H,H-8),6.35(s,1H,H-6),5.50(d,J=7.2Hz,1H,H-1″),5.18(s,1H,4″-OH),4.88(s,1H,2″-OH),4.53(s,1H,3″-OH),4.48(s,1H,6″-OH),3.84(s,3H,4′-OCH3),3.82(s,3H,3′-OCH3),3.81(s,3H,3-OCH3),3.65(m,1H,H-5″),3.54(t,J=16.2Hz,1H,H-3″),3.37-3.47(m,4H,H-2″,H-4″,H-6″);13C-NMR(DMSO-d6,150MHz)δ:177.5(C-4),165.2(C-7),161.5(C-2),156.5(C-5),156.0(C-9),151.0(C-4′),148.0(C-3′),133.8(C-3),122.4(C-1′),121.7(C-6′),112.8(C-2′),111.1(C-5′),105.3(C-10),101.6(C-1″),98.1(C-6),92.0(C-8),76.0(C-2″),73.1(C-4″),71.3(C-4″),68.0(C-5″),60.3(C-6″),56.1(4′-OCH3),56.0(3′-OCH3),55.6(7-OCH3);ESI-MS m/z:505[M-H]-,507[M+H]+。
实施例29
化合物16的合成
化合物12(50mg,0.077mmol)溶于20mL无水甲醇中,加入5mg甲醇钠,在50℃条件下反应,TLC监测反应,原料点消失停止,冷却至室温,减压回收溶剂得黄色粗品,经硅胶柱色谱(二氯甲烷/甲醇=100∶0 to 5∶1)得黄色固体30mg,产率81.1%。1H-NMR(DMSO-d6,600MHz)δ:12.53(s,1H,5-OH),7.74(dd,J=2.4,1.8Hz,1H,H-6′),7.49(d,J=2.4Hz,1H,H-2′),6.97(d,J=9.0Hz,H-5′),6.35(s,1H,H-8),6.14(s,1H,H-6),5.36(d,J=7.2Hz,1H,H-1″),5.12(br-s,1H,4″-OH),4.83(br-s,1H,2″-OH),4.42(br-s,2H,3″-OH,6″-OH),3.82(s,3H,4′-OCH3),3.41-3.61(m,6H,H-2″,H-3″,H-4″,H-5″,H-6″);13C-NMR(DMSO-d6,150MHz)δ:177.4(C-4),165.1(C-7),161.2(C-2),156.4(C-5),155.7(C-9),150.0(C-4′),146.0(C-3′),133.8(C-3),122.6(C-1′),121.7(C-6′),115.5(C-2′),111.3(C-5′),103.7(C-10),101.8(C-1″),99.0(C-6),93.7(C-8),75.9(C-2″),73.2(C-3″),71.2(C-4″),67.9(C-5″),60.2(C-6″),55.6(4′-OCH3);ESI-MS m/z:477[M-H]-,479[M+H]+。
实施例30
化合物17的合成
化合物9(130mg,0.2mmol)溶于5mL干燥的DMF中,加入无水K2CO3(28mg,0.2mmol)和溴化苄(26μL,0.2mmol),于室温条件下搅拌24h后,加入30mL冰水,用3%稀盐酸调节PH值至中性,用乙酸乙酯萃取(30mL×3),合并有机层,有机层用饱和食盐水洗涤(50mL×2),无水MgSO4干燥,过滤,浓缩滤液,得黄色油状粗品,经硅胶柱色谱(环己烷/V乙酸乙酯=2∶1),得黄色油状物91mg,产率61.9%。1H-NMR(DMSO-d6,600MHz)δ:12.49(s,1H,5-OH),9.41(s,1H,3′-OH),7.61(d,J=2.4Hz,1H,H-2′),7.59(dd,J=6.6,1.8Hz,1H,H-6′),7.45(d,J=7.8Hz,2H,7-O-Bn-Ar),7.39(t,J=15.6Hz,2H,7-O-Bn-Ar),7.35(t,J=14.4Hz,1H,7-O-Bn-Ar),7.04(d,J=8.4Hz,1H,H-5′),6.83(d,J=1.8Hz,1H,H-8),6.46(d,J=1.8Hz,1H,H-6),5.68(d,J=7.8Hz,1H,H-1″),5.34(t,J=19.2Hz,1H,H-6″),5.22(s,2H,5-O-Bn-CH2),5.12(t,J=17.4Hz,1H,H-6″),4.98(t,J=19.2Hz,1H,H-5″),3.86-3.95(m,3H,H-3″,H-2″,H-4″),3.84(s,3H,4′-OCH3),2.01(s,3H,CH3CO),1.95(s,3H,CH3CO),1.94(s,3H,CH3CO),1.80(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.0(C-4),169.8,169.5,169.34,169.3(4C,Ac-CO),164.4(C-7),160.9(C-2),157.2(C-5),156.3(C-9),150.5(C-4′),145.9(C-3′),136.1(7-O-Bn-Ar),133.3(C-3),127.9-128.6(5C,7-O-Bn-Ar),121.9(C-1′),121.1(C-6′),116.1(C-2′),111.3(C-5′),105.1(C-10),98.7(C-1″),98.6(C-6),93.3(C-8),71.9(C-3″),71.4(C-2″),70.6(C-5″),67.8(C-4″),61.0(C-6″),55.6(4′-OCH3),20.5,20.4,20.3,20.1(4C,Ac-CH3);ESI-MS m/z:735[M-H]-,737[M+]+。
实施例31
化合物18的合成
化合物12(150mg,0.23mmol)溶于5mL干燥的DMF中,加入无水K2CO3(32mg,0.23mmol)和溴化苄(30μL,0.2mmol),于室温条件下搅拌24h后,加入30mL冰水,用3%稀盐酸调节PH值至中性,用乙酸乙酯萃取(30mL×3),合并有机层,有机层用饱和食盐水洗涤(50mL×2),无水MgSO4干燥,过滤,浓缩滤液,得黄色油状粗品,经硅胶柱层析(环己烷/乙酸乙酯=2∶1)得黄色油状物94mg,产率55%。1H-NMR(DMSO-d6,600MHz)δ:12.49(s,1H,5-OH),9.24(s,1H,3′-OH),7.62(dd,J=8.4,2.4Hz,1H,H-6′),7.53(d,J=2.4Hz,1H,H-2′),7.44(d,J=7.2Hz,2H,Bn-Ar-H-2,Bn-Ar-H-6),739(t,J=15.0Hz,2H,Bn-Ar-H-3,Bn-Ar-H-5),7.33(t,J=14.4Hz,1H,Bn-Ar-H-5),7.04(d,J=9.0Hz,1H,H-5′),6.81(d,J=1.8Hz,1H,H-8),6.45(d,J=2.4Hz,1H,H-6),5.62(d,J=7.8Hz,1H,H-1″),5.24-5.26(m,1H,H-6″),5.22(s,2H,7-O-Bn-CH2),5.17-5.20(m,2H,H-5″,H-6″),4.17(m,1H,H-2″),3.85(s,3H,4′-OCH3),3.82-3.84(m,2H,H-3″,H-4″),2.12(s,3H,CH3CO),2.03(s,3H,CH3CO),1.91(s,3H,CH3CO),1.76(s,3H,CH3CO);13C-NMR(DMSO-d6,150MHz)δ:177.1(C-4),170.0,169.5,169.5,169.4(4C,Ac-CO),164.3(C-7),160.9(C-2),157.3(C-5),156.3(C-9),150.4(C-4′),146.0(C-3′),136.1(Bn-Ar-C-1),133.4(C-3),128.6(2C,7-O-Bn-Ar-C-3,5),128.2(7-O-Bn-Ar-C-4),127.9(7-O-Bn-Ar-C-2,6),122.2(C-1′),121.4(C-6′),116.0(C-2′),111.2(C-5′),105.1(C-10),98.9(C-1″),98.7(C-6),93.3(C-8),70.2(2C,7-O-Bn-CH2,C-2″),70.1(C-3″),69.2(C-5″),67.1(C-4″),60.9(C-6″),55.7(4′-OCH3),20.6,20.,20.4,20.2(4C,Ac-CH3);ESI-MS m/z:735[M-H]-,737[M+H]+。
实施例32
药理学实验:
用十万分之一天平精密称取样品,然后用DMSO溶解成适合的浓度作为贮备液,在-20℃下保存,使用前再用SUM149细胞培养液稀释成所需的浓度。
常法培养SUM149细胞,待其增殖至细胞交联70-80%时,吸去培养基,加入2mL0.25%胰蛋白酶溶液,放入37℃、5%CO2培养箱消化2-3min,至显微镜下观察大部分细胞已不再贴壁,加入6mL培养基终止消化,得到细胞混悬液,于500rpm的低温离心机内离心3min,吸去上清液,重新加入6mL培养基,吹散细胞,测定细胞密度。将细胞密度调整至3×103/孔,接种于96孔板,放于37℃、5%CO2培养箱培养24h,随后加待测试样品,实验分组为:空白组和不同剂量组,根据前期预试验,每个化合物测试4个浓度,每个浓度3个复孔,每孔200μL培养液。加毕,放于37℃、5%CO2培养箱培养48h后,吸去培养液,加入新鲜配制MTS试剂,置于37℃培养箱2h,置于酶标仪490nm处测OD值,读数转到Graphpad Prism软件计算IC50等数值。
结果表明(如表2所示):化合物1b-1m、1、3表现出较强的对人三阴性乳腺癌细胞的生长抑制作用,其IC50值范围为1.38-11.98μM;而其余的化合物则无明显细胞毒活性,在最大测试浓度(20μM)下的抑制率<50%。
表2化合物1b-1m、1、3对人三阴性乳腺癌细胞系
SUM 149的生长抑制作用(n=3)
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010701196.2A CN113956227A (zh) | 2020-07-20 | 2020-07-20 | 黄酮类化合物及其合成方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010701196.2A CN113956227A (zh) | 2020-07-20 | 2020-07-20 | 黄酮类化合物及其合成方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113956227A true CN113956227A (zh) | 2022-01-21 |
Family
ID=79459493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010701196.2A Pending CN113956227A (zh) | 2020-07-20 | 2020-07-20 | 黄酮类化合物及其合成方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113956227A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110804056A (zh) * | 2019-11-06 | 2020-02-18 | 浙江工业大学 | 具有金雀花碱-黄酮类骨架的化合物及其合成方法与应用 |
-
2020
- 2020-07-20 CN CN202010701196.2A patent/CN113956227A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110804056A (zh) * | 2019-11-06 | 2020-02-18 | 浙江工业大学 | 具有金雀花碱-黄酮类骨架的化合物及其合成方法与应用 |
Non-Patent Citations (1)
Title |
---|
ASHA SRINIVASAN等: "Quercetin Regulates β-Catenin Signaling and Reduces the Migration of Triple Negative Breast Cancer", 《MOLECULAR CARCINOGENESIS》, vol. 55, 12 May 2015 (2015-05-12), pages 743 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3524844A (en) | Epipodophyllotoxin glucoside derivatives | |
CN101671375B (zh) | 一种溴代四乙酰葡萄糖及其合成方法与它的用途 | |
Abe et al. | Trypanocidal constituents in plants 6. Minor withanolides from the aerial parts of Physalis angulata | |
Kouno et al. | Two new iridolactones and their glycosides from the roots of Patrinia scabra | |
US3408441A (en) | Epipodophyllotoxin-beta-d-glucosides and derivatives thereof | |
CN113387915B (zh) | 一种桉烷型倍半萜内酯类tbb衍生物及其制备方法、用途 | |
AU2020103289A4 (en) | Preparation and Application of Alkaloid Derivatives for Reversing Human Tumor Drug Resistance and Anti-canine Breast Cancer | |
CN103992333B (zh) | 色原酮二聚体衍生物及其制备方法和用途 | |
CN102086219A (zh) | 具有抗癌活性的蒽环类抗生素简单结构类似物及制备方法 | |
CN105503804A (zh) | 槲皮素-3-o-乙酸酯的合成及在抗肿瘤方面的应用 | |
CN113956227A (zh) | 黄酮类化合物及其合成方法和用途 | |
Chen et al. | Bauhinin, a new nitrile glucoside from Bauhinia championii | |
CN110117307B (zh) | 楤木皂苷衍生物及其制备方法和用途 | |
JP2006206489A (ja) | 抗癌剤 | |
CN115073406B (zh) | 一种桉烷型倍半萜内酯类tba衍生物及其用途 | |
EP2716293B1 (en) | Anti-tumor agent | |
CN115057839B (zh) | 一种桉烷型倍半萜烯内酯化合物及其制备和用途 | |
CN113956224A (zh) | 半合成黄酮类化合物及其抗炎用途 | |
NISHIMURA et al. | Tannins and Related Compounds. XLVI.: Isolation and Structures of Stenophynins A and B, Novel Tannins from Quercus stenophylla MAKINO | |
Zhou et al. | Biotransformation of 4-phenylcoumarin by transgenic hairy roots of Polygonum multiflorum | |
Hossain et al. | A new flavonol glycoside from the seeds of Zea Mays | |
CN103570780B (zh) | 鬼臼毒素糖苷物和酰化糖苷物及其药物组合物和其制备方法与应用 | |
Sakurai et al. | Chemical studies on the mistletoe. V. The structure of taxillusin, a new flavonoid glycoside isolated from Taxillus kaempferi. | |
CN111995647B (zh) | 从绿萼梅中分离的具有抗肿瘤活性的化合物及其制备方法 | |
CN100506777C (zh) | 一类具有抗癌活性的苯并双萘醌衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |